Chronic Opioid Users May Wish to Taper Opioid Use

Share this content:
Chronic Opioid Users May Wish to Taper Opioid Use
Chronic Opioid Users May Wish to Taper Opioid Use

WEDNESDAY, Feb. 21, 2018 (HealthDay News) -- Many patients with non-cancer-related chronic pain prescribed long-term opioids may wish to taper their opioid use, according to a research letter published online Feb. 19 in JAMA Internal Medicine.

Beth D. Darnall, Ph.D., from the Stanford University School of Medicine in Palo Alto, Calif., and colleagues conducted a study in which patients with non-cancer-related chronic pain prescribed long-term opioids at a community pain clinic were given education about the benefits of opioid reduction. Physicians offered to partner with patients to gradually reduce their dosages of opioids over four months. Seventy-five percent of 110 eligible patients (82 patients) agreed to taper their opioid dosages; participants received a self-help book and an individually designed taper.

The researchers found that 38 percent of the 82 enrolled patients did not complete a four-month follow-up survey and were considered to have dropped out. There was a negative correlation for depression and a positive correlation for baseline marijuana use with study completion. The baseline median morphine equivalent daily dose (MEDD) was 288 mg among study completers, with a median six-year duration of opioid use. The median MEDD was reduced to 150 mg after four months. Opioid reduction was not associated with increased pain intensity or pain interference.

"Our findings suggest that a substantial fraction of patients at a pain clinic may wish to engage in voluntary opioid tapering," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »